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Operations on patients with advanced heart failure carrysubstantial mortality, but this group has much to gainif they survive. Conventionally, the intra-aortic bal-loon pump (IABP) is used to assist weaning from
cardiopulmonary bypass (CPB), but postischemic stunning may
further impair myocardial function. This results in renal shutdown
and deranged metabolic status. In established cardiogenic shock,
attempted salvage with a left ventricular assist device (LVAD)
carries a 50% to 75% mortality.1,2 To improve outcome in bor-
derline survival situations, we decided to wean directly from CPB
to a short-term centrifugal blood pump.
Methods
The patients at highest risk are selected before surgery. Candi-
dates may have left ventricular ejection fraction less than 20%,
impaired renal function, or aortoiliac disease precluding IABP
use. LVAD implantation is undertaken during 30 minutes of
reperfusion, before discontinuation of CPB. Conduits for the
inflow and outflow cannulas are used to improve the safety of
decannulation (Figure 1).
The Levitronix CentriMag pump (Levitronix LLC, Waltham,
Mass) has been described previously.1 The pump head priming
volume is 31 mL. The system is filled during reperfusion and
deairing of the native heart. When the patient is weaned from CPB,
the LVAD provides 3 to 4 L/min flow. Antegrade cardiac ejection
provides systemic pulsatility. Combined output from the device
and the left ventricle is around 3.0 L/m2 · min. Transesophageal
echocardiography confirms the position of the inflow cannula and
the efficacy of deairing.
After protamine, the sternotomy is closed to allow extuba-
tion during support. To minimize bleeding, no anticoagulation
is given for 12 hours. Once the chest tube drainage is less than
50 mL/h, heparin infusion provides an activated partial throm-
boplastin time ratio of 1.5 to 2.5. Myocardial function is as-
sessed daily with pump flow turned down to 2.0 L/(m2 · min).
Postischemic dysfunction normally resolves during 3 to 7 days.
After sustainable improvement has been achieved, the pump is
switched off, the cannulas are withdrawn, and the grafts are
ligated close to their insertion.
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Figure 1. Tube of descending aortic homograft (8 cm length  10
mm diameter) is sewn to incision at junction of superior pulmo-
nary vein with left atrium. Through this conduit is introduced 32F
right-angled, wire-reinforced venous cannula into center of left
atrium. Ligatures are placed around homograft to retain inflow
cannula in position. Distal end of venous cannula is brought
through skin below sternotomy wound and then filled by raising
left atrial pressure. Dacron polyester fabric graft (8 mm) is then
sewn to ascending aorta with side clamp. Straight arterial inflow
cannula (22F) is inserted through this graft, secured in place by
ligatures, and brought out through skin adjacent to venous
cannula.
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Clinical Summaries
Five consecutive case studies are summarized in Table 1. All
patients had severe symptoms (New York Heart Association func-
tional class IV) and were considered at high risk for conventional
surgery. Patients 1, 2, 3, and 5 had an IABP during anesthetic
induction. Patient 4 had aortoiliac occlusion. None required reen-
try for bleeding. After the operation, the IABP was kept in place
for 24 to 36 hours after removal of the LVAD. Patients 2 and 4
required hemofiltration for renal impairment. There were no pump-
related adverse events.
Patient 2 had extensive inferior myocardial infarction with
biventricular failure. Forty-eight hours after repair of septal rup-
ture, myocardial function was considered incompatible with re-
covery, and hepatic failure ensued. Treatment was then withdrawn.
Patient 5 returned to the operating room for pump removal on day
3, but this was deferred for 3 days after observation of the heart.
All 4 patients who walked into the hospital were discharged.
Each has shown marked symptomatic relief and improvement in
left ventricular function.
Discussion
Heart failure surgery is an evolving specialty in which risk man-
agement plays an important role. As risk profile increases, there
is a need for reliable short-term circulatory support to contain
mortality. The rationale for elective LVAD deployment is straight-
forward. The failing heart pumps more than 7000 L of blood per
day against an increased afterload. A dilated heart has greater
wall tension and increased myocardial energy demand but suf-
fers reduced subendocardial blood flow. After surgery, ischemia-
reperfusion injury may trigger the downward spiral into cardio-
genic shock and multiorgan failure. Inotropic agents temporarily
elevate systemic blood pressure, but they exert deleterious effects
by increasing heart rate, afterload, and subendocardial ischemia.3
In contrast, the LVAD unloads the ventricle, boosts coronary and
systemic blood flows, and promotes myocardial recovery. Some
inotropic support may be required to sustain right ventricular
contractility.
Conventionally, LVADs are deployed only when death appears
certain, but established cardiogenic shock may not be reversible.1,2
The willingness to use LVAD technology preemptively to prevent
deterioration and promote recovery depends on the safety of the
system, the requirement for technical support, and the cost. For
recovery after ischemic arrest, the support duration is usually less
than 7 days. In this time frame, the Levitronix pump is reliable,
safe, and effective. It is readily managed by nursing staff and
easily portable. Reoperation for bleeding and decannulation prob-
lems are avoided by the use of conduits.
To date this LVAD has been used in more than 300 patients for
up to 64 days. The predominant indication (45%) has been salvage
postcardiotomy support (mean of 9 days), with 53% survival. We
suspect that the 47% mortality could be reduced by anticipating
postoperative deterioration and using the blood pump electively to
prevent cardiogenic shock.
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TABLE 1. Patient details: Demographic characteristics, risk stratification, and clinical outcome
Case
Age
(y) Sex
Logistic
EuroSCORE Problem
Left ventricular
ejection
fraction (%)
Preoperative
serum
creatinine
(mol/L) Operation
Support
duration
(d) IABP
Postoperative
stay (d)
1 58 F 4 Diabetes, ischemic heart
disease; large anterolateral
scar; nongraftable
coronaries
15 83 Left ventricular
remodeling
4 Yes 10
2 51 M 77 Basal postinfarction VSD;
hemodynamic collapse
Not
applicable
334 Repair of VSD;
salvage
procedure
2 Yes Died (day 2)
3 68 M 8 Aortic stenosis; idiopathic
dilated cardiomyopathy
10 105 Aortic valve
replacement
4 Yes 14
4 62 M 31 Aortic stenosis; chronic renal
failure; aortoiliac occlusion
10 341 Aortic valve
replacement
5 No 23
5 58 M 13 Aortic stenosis; ascending
aortic aneurysm
15 94 Aortic valve and
ascending aortic
replacement
6 Yes 22
IABP, Intra-aortic balloon pump; F, female; M, male; VSD, ventricular septal defect.
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